32
Participants
Start Date
January 27, 2012
Primary Completion Date
March 12, 2018
Study Completion Date
March 12, 2018
icatibant
Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
Campbelltown Hospital, Campbelltown
Medizinische Universität Graz Hautklinik, Graz
Penn State University, Hershey
Institute for Asthma and Allergy, PC, Chevy Chase
Unidad de Alergia, Edif. Consultas Externas, Planta Baja HOSPITAL UNIVERSITARIO LA PAZ, Madrid
University of South Florida, Tampa
Toledo Institute of Clinical Research, Toledo
Bernstein Clinical Research Center, LLC, Cincinnati
University Hospital, Pediatric Pulmonology and Allergy Unit, Valencia
Sheba Medical Center Allergy and Immunology Angioedema Center, Tel Litwinsky
Johannes-Gutenberg University Clinical Research Center, Mainz
Klinikum der Johann Wolfgang Goethe University, Frankfurt
Washington University School of Medicine, St Louis
Tel Aviv Sourasky Medical Center, Pulmonology and Allergy Unit, Tel Aviv
HZRM Hämophilie Zentrum Rhein Main GmbH, Walldorf
Breathe America, Shreveport
Oklahoma Institute of Allergy and Asthma Clinical Research, LLC, Oklahoma City
AARA Research Center, Dallas
University of Naples Federico II, Dipartimento di Medicina Interna, Naples
Children's Hospital Los Angeles, Los Angeles
Allergy Asthma Dermatology Research Center, Lake Oswego
Boston Children's Hospital, Boston
McMaster University, Hamilton
Hospital Infantil Universitario de San Jose, Bogota
Bnai Zion Medical Center, Allergy and Immunology Institute, Haifa
Heim Pal Childrens Hospital, Budapest
Lead Sponsor
Shire
INDUSTRY